Intro from Barbara White,
M.D.
Stiefel, a GSK company:
Advancing Research Technology

When I joined Stiefel this spring, I knew I would have the opportunity to work on groundbreaking research not only benefitting Stiefel, but the entire dermatology industry.

Stiefel maintains a diverse pipeline with the potential to bring new dermatologic therapies to market, and to help us improve the existing formulations of our products. It is exciting to join a company I have admired, especially when I realized the enormous potential that Stiefel has to spearhead new breakthroughs in dermatologic compounds as a result of being integrated with GlaxoSmithKline.

As a leader in dermatologic pharmaceutical research, Stiefel’s scientific team is comprised of the industry’s leading experts in preclinical and clinical development. Our research capabilities span the globe, allowing us to meet the needs of patients and physicians worldwide.

Today I would like to introduce you to the members of our Research & Development team, who together are making important discoveries for Stiefel and for patients.

Stiefel is proud to put our resources toward this great cause, and we hope to inspire the Dermatology community to join the effort and play a part in helping people with albinism avoid skin cancer.

Regards,

Barbara White
Head, Global Research & Development
Stiefel, a GSK company
barbara.a.white@stiefel.com
+1 919 315 2896

 

A Message from Bill Humphries
(President, Dermatology Stiefel, a GSK company)

September 2011

Helping to Prevent Skin Cancer

As a global leader in skin health, Stiefel, a GSK company, is committed to improving the quality of life for those affected by skin conditions around the world. Whether we’re investing in our pipeline, expanding our product offering into new countries, or giving back to the community, at our core we’re always thinking about supporting patient needs above all else. To that end, we’re truly excited to share news with you about one of our latest charitable programs.

Hats On For Skin Health is a global collaboration with the International League of Dermatological Societies (ILDS) to reduce the devastating effects of skin cancer among albinos living in Tanzania. Research shows that 100% of albinos in this region will present with some form of skin damage by the age of 10 years old.

Many albinos in Tanzania are not educated about the importance of sun protection and the consequences of sun damage. Even if they are aware, many can’t afford sun-protective items like hats or long-sleeved clothing. That’s where we can help. Funds raised through Hats On For Skin Health will be used by ILDS to purchase hats and other sun-protective items. The ILDS’ Regional Dermatology Training Center will ensure that the much-needed items are put into the hands of albinos throughout the region.

You Can Help, Too

Stiefel is proud to put our resources toward this great cause, and we hope to inspire the Dermatology community to join the effort and play a part in helping people with albinism avoid skin cancer.

To learn more please about Hats On For Skin Health, visit www.hatsonforskinhealth.org.

Warm regards,

Bill Humphries
President, Dermatology
Stiefel, a GSK company

 

Darren Coleman
(Vice President, Global Strategy & Operations)

September 2011

The Road Ahead : Q&A with Darren Coleman

Stiefel has come a long way in the last two years, but there is still much work to be done to deliver the valuable medicines and skin health solutions that patients need. Darren Coleman, vice president, Global Strategy and Operations, explains how Stiefel is strategically planning to meet the dermatology industry’s requirements for the future.

Q: How is Stiefel planning for the future?
A: Stiefel has always listened to our healthcare provider customers and patients, so we believe we have good insight into their needs. But having this knowledge is simply not enough. We’re combining these insights and our passion for increasing the standard of care for skin conditions with a foundation in research and development to bring high-value, quality products to patients. This foundation includes access to a library of molecules untapped for their dermatology potential, industry-leading scientists with expertise in discovery, and product development capabilities that will optimize our ability to turn new compounds into safer and more-efficacious medicines.

Q: What does Stiefel look like in 10 years?
A: Our vision for Stiefel in 10 years is to be delivering novel medicines, founded in compelling scientific research, that treat real, unmet skin health needs. And we want to deliver those products to patients on a global scale.

Q: How would you say Stiefel is positioned for the future?
A: There is no doubt that all pharmaceutical companies are striving to develop better products with new mechanisms of action that are more valuable to patients, physicians and payers alike. What Stiefel brings to the table is a distinct understanding of skin health. This unique perspective is a result of our steady, singular focus on dermatology that spans more than 160 years. That’s not to say we’re resting on our laurels; instead we are using our expertise to recognize where patients and physicians need new solutions and using these insights to drive our research and development.

Q: What is Stiefel’s strategy for the future?
A: Our goal is simple: bring better medicines to more patients around the world. Currently, approximately 64 percent of dermatology patients around the world have access to Stiefel medicines, but in the future we hope to bring our products to more than 98 percent of them. We’re positioned to do this in three ways:

• In the near term, we’re working on bringing our entire current product portfolio to countries that presently only have access to a portion of them. For example, we’re working to bring valuable VersaFoam® products to countries in Latin America.
• We’re also working to enter new markets, such as Japan, where GSK has an established presence.
• Lastly, we’re striving to discover new chemical entities for dermatology that will enable us to develop medicines which bring better treatments to patients, meeting needs that are currently unmet.

Q: What should our customers expect from us?
A: Our customers, and their patients, should continue to expect us to listen. Stiefel built its reputation by listening to and collaborating with skin health professionals. We know that if we continue to listen and to collaborate, the result will be greater innovations to dermatology.

Q: How are we reshaping dermatology?
A: Dermatology is in need of new chemical entities. If we can deliver these, it will inevitably drive the practice of dermatology forward.